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Abstract
By the end of 2017, an estimated 68.5 million people were displaced from their homes worldwide, of whom 25.4
million were refugees. The transmission and globalization of multi-drug resistant tuberculosis during refugee
migration is a now priority issue in the public health agenda. Political and scientific commitment at the highest
national and international levels will be critical to intensifying action in promoting improved health services for
migrants and refugees.
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Vulnerability of refugees to tuberculosis (TB)
The 2018 United Nations High Commission for Refugees
Report indicates that, by the end of 2017, an estimated
68.5 million people had been displaced from their homes
worldwide, including 25.4 million external refugees and
43.1 internally displaced people escaping conflict and per-
secution [1]. These figures represented an overall increase
of 2.9 million people compared to those of 2016. Over the
past 6 years, a major exodus of men, women, and children
has been reported from Syria, Myanmar, Bangladesh, Iraq,
Yemen, Sudan, Burundi, Central African Republic, the
Democratic Republic of the Congo, and Ukraine, among
other countries [1]. Due to the adverse living conditions,
close contact, poor nutrition, and mental and physical
stress, refugees are at an increased risk of acquiring a
range of infectious diseases, in particular diarrheal dis-
eases, hepatitis, arthropod-borne and waterborne parasitic
diseases, and respiratory tract infections, including TB [2].
The combination of these risk factors and poor access to
TB health services increases refugees’ vulnerability to ac-
quiring TB infection, which then progresses to TB disease.
Additionally, delays in diagnosis results in poor treatment
outcomes and continued transmission in the community.
The refugee crisis, coupled with the emergent transmis-
sion and globalization of antibiotic-resistant pathogens,
including multi-drug resistant TB (MDR-TB), during mass
gatherings and migration, have now become a priority
issue in the international public health agenda [3, 4].
Global TB rates
The World Health Organization’s (WHO) annual Global
Tuberculosis Report of 2018 indicates that TB remains
the most important cause of death from an infectious
disease worldwide [5]. An estimated 10 million people
developed TB in 2017, with a further 4 million people
with TB remaining undiagnosed and untreated. At the
current rates of global TB control efforts, WHO’s goal
to end the global TB epidemic by 2030 will not be
achieved [6]. Further, the paucity of data on the inci-
dence of most diseases, including TB, among migrants
and refugees hampers public health action. For example,
the WHO TB Report provides no specific data on global
TB rates in refugees or migrant populations. Addition-
ally, there are an estimated 1.4 billion people worldwide
with latent TB infection (LTBI), in whom TB could re-
activate in conditions of stress or immunosuppression.
Indeed, a significant proportion of active TB cases result
from reactivation of LTBI in migrants under stress, with
poor nutrition and living in inadequate conditions.
Therefore, the issue of ensuring optimal TB services for
refugees (which should be an integral part of the health
services they receive) in order to ensure the health of
the wider community has been long debated [7–9].
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Global spread of multidrug-resistant (MDR) TB
In 2017, an estimated 558,000 people developed drug-re-
sistant TB [5], of whom an estimated 458,000 had
MDR-TB (defined as resistance to the two first-line TB
drugs, rifampicin and isoniazid). As a result, only half of
patients with MDR-TB are cured after receiving appro-
priate treatment. MDR-TB continues to spread globally
and is a major threat to global health security. Indeed, it
is estimated that, over the next 35 years, MDR-TB will
result in the deaths of approximately 75 million people
[10]. MDR-TB treatment is expensive, associated with
toxic side-effects, and observed therapy and dedicated
patient support are required to ensure adherence and
cure as well as to minimize the risk of emergence of ex-
tensively drug-resistant TB [11].
MDR-TB in refugees
Accurate data on the global prevalence of MDR-TB in refu-
gee and displaced populations worldwide is not available.
Despite being recognized as a priority global health issue,
accurate global data on the epidemiology, transmission dy-
namics, access to health services, and impact of TB in refu-
gees on local health services and populations in developing
countries have not been readily forthcoming [12]. The past
6 years have seen waves of refugees migrating to Europe. In
anticipation of the threat of importation of infectious dis-
eases to western Europe, a flurry of activity by public health
systems have established, screening procedures for refugees
and migrants from eastern Europe, Africa, Asia, and the
Middle East. Nevertheless, an increasing number of reports
on TB in migrants and refugees within Europe shows that
the hysteria surrounding the importation of MDR-TB by
refugee populations appears to be unfounded [13, 14]. In a
systematic evaluation of data on MDR-TB and migration in
Europe [15], all MDR-TB cases diagnosed in Austria, the
Netherlands, and Norway, as well as a high proportion of
those reported in other European countries (90% in the
UK, 89% in France, 87% in Italy, and 94% in Germany), oc-
curred in migrants. However, these refugees were already at
higher risk of contracting MDR-TB in their country of ori-
gin, where high MDR-TB rates prevail. A study from
Norway showed that migrants from high TB-incidence
countries had little influence on the transmission of TB in
Norway [16].
In the BMC Medicine Migrant and Refugee Health
collection (https://www.biomedcentral.com/collections/
migrant-and-refugee-health), two studies discuss the
issue of refugees and MDR-TB. Pescarini et al. [17] de-
scribe a cross-sectional study in a central area of Sao
Paulo, Brazil, focusing on migration and TB transmis-
sion utilizing molecular genotyping. Cross-transmission
between migrants and Brazilians was confirmed, yet the
contribution by migrants was not substantial. Nellums et
al. [18] conducted a systematic review and metanalyses
of 15 selected studies reporting MDR-TB treatment out-
comes for 258 migrants and 174 non-migrants in Euro-
pean countries. The estimated rate of adherence to
MDR-TB treatment across all patients was 71% .
MDR-TB treatment adherence rates among migrants in
high-income, low TB-incidence countries approached
global targets for treatment success (75%) and were
comparable to rates in non-migrants. Therefore, ap-
proximately 70% of migrant and non-migrant patients
appear to adhere to MDR-TB treatment. Nevertheless,
only 50% of MDR-TB patients worldwide successfully
complete treatment, with nearly 25% being lost to
follow-up [5]. This indicates the importance of increas-
ing adherence by reducing the associated social risk fac-
tors, which in turn could achieve higher MDR-TB
treatment completion rates and enable reductions in
transmission.
TB screening in refugees
Urgent calls for action have been voiced to ensure access
to early diagnosis and care of TB among refugees [9]. In-
deed, most high-income countries now have dedicated
refugee TB screening policies. A survey related to TB
control programs in 29 member states of the
Organization for Economic Cooperation and Develop-
ment in 2010 [7] showed that 86% and 55% of these
countries had TB screening programs for active TB and
LTBI, respectively. Ideally, baseline TB screening should
be completed for every refugee child and adolescent on
arrival, with a subsequent follow-up over the next 2
years. This approach creates substantial pressure on the
limited healthcare resources of ‘host countries’. There-
fore, a comprehensive framework for the prevention and
reduction of the TB burden among migrants and refu-
gees, in line with the WHO End TB strategy, has been
suggested [2]. The framework emphasizes the conduct
of priority operational research to define the TB burden
in refugee situations, the challenges of access to health-
care, and the biomedical, social and structural determi-
nants of TB across the full migration pathway, as well as
a cascade of care policies ranging from the prevention to
the diagnosis and treatment of TB. The data would form
the basis of a developing migrant- and refugee-sensitive
care and prevention program, with supportive intersec-
toral policies and systems.
Political commitments at the highest national and
international levels provide hope for the improvement of
the currently appalling status quo of global TB [19]. Fol-
lowing the first global ministerial conference on TB in
Moscow in 2017 [20], and in advance of the UN
high-level meeting on TB in 2018, the WHO, the Stop
TB Partnership, and The Global Fund to Fight AIDS,
Tuberculosis and Malaria launched a joint initiative to
scale-up the End TB response towards universal access
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to TB prevention and care. The “FIND. TREAT. ALL.
#EndTB” initiative [21] aims to scale-up the global re-
sponse towards universal access to TB prevention and
care, with an ambitious target to diagnose, treat, and re-
port 40 million people with TB, including 3.5 million
children and 1.5 million people with drug-resistant TB,
between 2018 and 2022.
Conclusions
Achieving the WHO TB control targets will require the
combined efforts of many stakeholders, including do-
nors, governments, civil society, advocacy groups,
TB-affected communities, the private sector, and global
public health bodies, to accelerate access to prevention
and care as well as to monitor progress [19]. The initia-
tive encompasses all countries, with priority given to the
30 high TB burden countries listed in the WHO 2018
Global TB Report [5]. It is critical that the specific issue
of TB in refugees is incorporated and implemented in
these initiatives. Achieving universal coverage and access
to healthcare is an acknowledged human right, as
enshrined in the United Nations Universal Declaration
of Human Rights Article 25. Political and scientific com-
mitment at the highest national and international levels
will be critical to intensifying action in promoting the
health of migrants on the road to achieving the WHO
End TB targets.
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